DYNC2LI1 Knockout K-562 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated by disrupting the DYNC2LI1 gene in the K-562 human chronic myelogenous leukemia lymphoblast cell line. This product provides a loss-of-function model to study the biological roles of DYNC2LI1, a light intermediate chain of the cytoplasmic dynein-2 complex essential for retrograde intraflagellar transport (IFT) in primary cilia. The polyclonal format reflects a heterogeneous mix of edited cells, avoiding clonal selection and enabling population-level functional analyses without the bias introduced by monoclonal isolation.
The host K-562 cell line was established from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in blast crisis. K-562 cells harbor the Philadelphia chromosome (BCR-ABL1 fusion gene) and serve as a widely used model for hematopoietic differentiation, capable of undergoing erythroid and megakaryocytic lineage commitment under appropriate stimuli. Their robust growth and well-characterized signaling landscape make them suitable for mechanistic studies, including ciliary biology research in the context of leukemia.
DYNC2LI1 encodes a light intermediate chain that associates with the dynein-2 motor complex, powering the transport of ciliary proteins from the tip to the base. This retrograde IFT is critical for ciliogenesis, ciliary length maintenance, and Hedgehog signaling. DYNC2LI1 interacts directly with DYNC2H1, DYNC2I1/2, and IFT-B components IFT88 and IFT172. Its function is regulated by RFX transcription factors and cell cycle cues. Disruption of DYNC2LI1 impairs ciliary localization of SMO and GLI proteins, attenuating pathway output. Mutations in DYNC2LI1 are linked to short-rib polydactyly syndromes and Jeune asphyxiating thoracic dystrophy, highlighting its importance in ciliary biology.
In the K-562 host background, DYNC2LI1 knockout allows exploration of both canonical cilia-dependent functions and potential cilia-independent roles of this dynein component in leukemia cells. While K-562 cells are not traditionally considered ciliated, they can form primary cilia under certain conditions, and recent evidence suggests cilia-related proteins may modulate cancer cell proliferation and drug sensitivity. Thus, this model opens avenues for investigating whether DYNC2LI1 influences leukemia cell biology through ciliary Hedgehog signaling or alternative mechanisms, such as affecting mitotic spindle orientation or intracellular trafficking.
Researchers can employ these polyclonal knockout cells for a broad range of applications, including functional characterization of DYNC2LI1 in ciliogenesis and Hedgehog signaling using immunofluorescence microscopy for ciliary markers (e.g., ARL13B, acetylated tubulin), RT-qPCR and Western blotting to assess DYNC2LI1 knockdown, and GLI-luciferase reporter assays to quantify pathway activity. Additional applications include cell proliferation assays, drug screening for ciliopathy-related compounds, and the investigation of cilia-independent functions in hematopoietic differentiation and leukemogenesis. For further technical details, please contact Ascent Research.
